In this study, the specificity of anti-Glypican-1 antibody MIL-38 towards urothelial carcinoma cells was utilised for their targeted labelling by UCNP coupled to MIL-38 and termed targeted UCNP nanoconjugates. Here, GPC1 is linked to urothelial carcinoma.